Dan Ruderman received his doctorate in theoretical physics from the University of California at Berkeley, followed by postdoctoral research at Cambridge University, USC, and the Salk Institute. Dr. Ruderman continued his scientific research in the industrial setting, first in solid tumor target discovery through integrative genomics at Berlex Biosciences, and then in proteomic biomarker discovery at Applied Minds.
He was Founding Scientist at Applied Proteomics, a biomarker company spun out from Applied Minds in 2007. Dr. Ruderman joined CAMM in 2011, where his research focuses on signaling dynamics in cancer cells and systems biology interpretations of high-dimensional cancer assays, such as gene expression, proteomics, and autoantibodies.
Fannie and John Hertz Foundation : Fellowship, 1989-1993
National Science Foundation/ North Atlantic Treaty Organization: Postdoctoral Fellowship, 1994
Phi Beta Kappa: Elected Member, 1988
President's Undergraduate Fellowship
National Science Foundation: Fellowship, 1993
Sloan Foundation: Postdoctoral Fellowship, 1996-1998
Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. Sci Rep. 2016 Oct 06; 6:34785. View in: PubMed
Flinders C, Lam L, Rubbi L, Ferrari R, Fitz-Gibbon S, Chen PY, Thompson M, Christofk H, B Agus D, Ruderman D, Mallick P, Pellegrini M. Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med. 2016; 8(1):54. View in: PubMed
Chiu CL, Patsch K, Cutrale F, Soundararajan A, Agus DB, Fraser SE, Ruderman D. Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016; 6:22435. View in: PubMed
Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. View in: PubMed
Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, Maccoss M, Tabb DL, Mallick P. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct 10; 30(10):918-20. View in: PubMed
Hughey CA, Minardi CS, Galasso-Roth SA, Paspalof GB, Mapolelo MM, Rodgers RP, Marshall AG, Ruderman DL. Naphthenic acids as indicators of crude oil biodegradation in soil, based on semi-quantitative electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom. 2008 Dec; 22(23):3968-76. View in: PubMed
Yamaguchi KD, Ruderman DL, Croze E, Wagner TC, Velichko S, Reder AT, Salamon H. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008 Mar; 195(1-2):116-20. View in: PubMed
Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, Ruderman DL, Dinter H, Zajchowski DA. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia. 2007 Jul; 9(7):601-13. View in: PubMed